Biotech News
Related news
BTAIBioXcel2026-05-28 11:00 EST
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
ZNTLZentalis2026-05-27 20:05 EST
Zentalis Strengthens Commercial Leadership with Appointments of Shannon Campbell to Board of Directors and Sarah Kelly as SVP of Commercial Strategy
GERNGeron2026-07-22 20:01 EST
Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GERNGeron2026-07-14 20:26 EST
Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
SNDXSyndax Pharmaceuticals2026-06-01 11:00 EST
Syndax to Host R&D Day Highlighting its Late-Stage Programs and Early-Stage Assets on July 14, 2026
NBIXNeurocrine Biosciences2026-07-23 20:05 EST
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
TEVATeva Pharmaceutical Industries2026-06-04 12:30 EST
Teva Expands European biosimilars portfolio with launch of AHZANTIVE® (aflibercept) biosimilar to Eylea®
ELVNEnliven Therapeutics2026-06-03 20:05 EST
Enliven Therapeutics to Host Webcast Conference Call to Discuss Phase 1 ELVN-001 Clinical Data Being Presented at EHA 2026 Congress
KYMRKymera2026-06-24 20:01 EST
Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors
ELVNEnliven Therapeutics2026-06-15 20:40 EST
Enliven Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters' Option to Purchase Additional Shares
BioXcel
BioXcel Therapeutics is a neuroscience and immuno-oncology company focused on using artificial intelligence to identify therapeutic candidates. Its story combines data-driven discovery with development-stage biotech execution.
Recent company news
BTAIBioXcel2026-05-28 11:00 EST
BioXcel Therapeutics Presents New Data from SERENITY At-Home Phase 3 Trial for Agitation Associated with Bipolar Disorders or Schizophrenia at 2026 ASCP Annual Meeting
BTAIBioXcel2026-05-15 11:00 EST
BioXcel Therapeutics Provides Business Update and Reports First Quarter 2026 Financial Results
BTAIBioXcel2026-04-17 11:00 EST
BioXcel Therapeutics Announces Virtual Event to Discuss Commercial Launch Plan Based on Market Opportunity Assessment for IGALMI® in the At-Home Setting
BTAIBioXcel2026-04-08 11:00 EST
BioXcel Therapeutics Announces Enrollment of First Patients in U.S. Department of War-Funded Study of BXCL501 (Sublingual Dexmedetomidine) for Treatment of Acute Stress Reactions
BTAIBioXcel2026-04-01 11:00 EST
BioXcel Therapeutics Announces Food & Drug Administration Acceptance of Supplemental New Drug Application for Use of IGALMI® in the At-Home Setting
Stock data
- Close
- 0.83 USD
- Market cap
- 36.74M USD
- Exchange
- NASDAQ
- Sector
- Biopharma
- Location
- United States